Introduction
The discovery of Australia antigen (hepatitis B surface antigen (HBsAg)) by Blumberg in 1965,' its association with serum hepatitis described by Prince in 19682 and the visualisation of the 42 nm infectious hepatitis B virus (HBV) particle by electron microscopy in 19703 led to research into the aetiology, treatment and prevention of serum hepatitis. Further serological markers of HBV and its mode of replication have been described,45 the HBV genome cloned6 and effective vaccines produced. 7 HBV infection is endemic in certain geographical areas with approximately 300 million HBsAg carriers worldwide. The carrier rate varies from country to country with 0-2-0.5% in Western Europe and 8-20% in South East Asia. Rates are generally higher in the tropics, amongst males and in urban communities.
HBV infection may be symptomatic or asymptomatic and is associated with a wide spectrum of inflammatory liver disease. This ranges from acute to chronic hepatitis and may ultimately lead to cirrhosis or primary hepatocellular carcinoma. In acute symptomatic infections, patients may present with malaise, lethargy, anorexia, headache, mild diarrhoea or upper right quadrant pain followed by jaundice and arthralgia.
The detection of HBV markers in the serum of patients with HBV infection is not only important for diagnosis but also for management and predicting the outcome of infection.
Hepatitis B markers HBsAg may be detected in the blood 2 to 8 weeks before the onset of hepatitis and persists during the acute phase. It Antigen expression may be prolonged and the production of antibodies to these antigens delayed in chronic HBV infection. Table 1 describes the interpretation of the serological markers detected after acute and chronic HBV infection and figure 1 demonstrates the relative concentrations of these serological markers. The specificity of assays in current use will vary from manufacturer to manufacturer. In general, the specificity of enzyme immunoassays may depend on the condition of the specimen. Haemolysed serum/plasma or serum/plasma containing red blood cells or bacteria may contain endogenous enzymes which react with the enzyme substrate and produce false-positive reactions. Samples containing the preservative sodium azide, a potent peroxidase poison, may produce falsenegative results in assays that use a peroxidase-labelled second antibody. Therefore, it is important to perform confirmatory tests on all reactive samples. Although this may be achieved by performing an alternative assay of similar sensitivity, a neutralisation test with anti-HBs is preferred.
Detection of HBeAg and anti-HBe
The detection of HBeAg and anti-HBe is usually accomplished in a single assay. The patient's serum is added to two wells of a microtitre plate coated with anti-HBe monoclonal antibodies. Anti-HBe monoclonal antibody conjugated to horseradish peroxidase is added to the first well to detect HBeAg. To detect anti-HBe, HBeAg is added to the second well followed by the anti-HBe enzyme conjugate. Competition between anti-HBe present in the patient's serum and the anti-HBe enzyme conjugate will result in a decrease in colour (fig 4) . HBcAg can then be detected with a radio-or enzyme-labelled anti-HBc monoclonal antibody.
Detection of anti-HBc
Total anti-HBc is usually detected in a competitive RIA or ELISA. Anti-HBc present in the patient's serum and a radio-or enzymelabelled anti-HBc compete for HBcAg bound to the solid phase. Therefore the proportion of conjugate bound to the HBcAg is inversely 
